AbCellera Biologics Inc. 8-K

What Happened

• AbCellera Biologics Inc. filed an 8-K reporting the results of its Annual Meeting of Shareholders held on June 11, 2026. As of the record date April 15, 2026, 305,264,947 common shares were outstanding and entitled to vote.
• Shareholders approved the election of John S. Montalbano, CFA, and Stephen R. Quake, D.Phil., as Class III directors (three-year terms), ratified Ernst & Young LLP as the company’s independent registered public accounting firm for fiscal 2026, and approved the non-binding advisory Say-on-Pay vote on executive compensation.

Key Details

• Record date and shares outstanding: 305,264,947 common shares (record date April 15, 2026).
• Proposal 1 — Directors elected:
  • John S. Montalbano: For 141,430,732; Against 12,723,342; Abstain 45,898.
  • Stephen R. Quake: For 149,019,960; Against 5,113,056; Abstain 66,956.
  • Broker non-votes for Proposal 1: 36,576,359 shares.
• Proposal 2 — Ratification of Ernst & Young LLP as auditor: For 189,927,972; Against 552,429; Abstain 295,930.
• Proposal 3 — Say-on-Pay (non-binding): For 142,831,950; Against 10,932,105; Abstain 435,917. Broker non-votes for Proposal 3: 36,576,359 shares.
• No other matters were submitted or voted on at the meeting.

Why It Matters

• The election of two Class III directors and the ratification of Ernst & Young LLP are routine corporate governance actions confirmed by shareholders; they affect board composition and the company’s external audit relationship.
• Approval of the Say-on-Pay vote indicates shareholder support for the company’s executive compensation policies (non-binding), which can influence future governance and compensation discussions.
• Vote totals, abstentions, and the sizable broker non-votes (36.6M shares) provide context on shareholder participation and the level of contested support for board and compensation matters.